The falling share price might suggest overrated stock or a potential opportunity. The company's poor performance could be a bad sign, but contrarian investors might see a turnaround.
$Hang Seng Index (800000.HK)$plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion. Pharmaceuticals were sold off.$REMEGEN (09995.HK)$once collapsed 27.5% to $22.8; last at $24.9, down 21%. $CLOVER BIO-B (02197.HK)$nosedived 9.6% to $0.47, hitting record low.$VIVA BIOTECH (01873.HK)$...
Investors are ignoring Luye Pharma Group's limited growth expectations, paying up for exposure to the stock. However, maintaining these prices may be difficult as this level of revenue growth is likely to weigh down the shares eventually.
LUYE PHARMA Stock Forum
Pharmaceuticals were sold off. $REMEGEN (09995.HK)$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B (02197.HK)$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH (01873.HK)$ ...
No comment yet